All In Biotech

Drug Trial Radar · NCT06220214

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Jul 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Alison StopeckAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram, but also collects additional images for digital breast tomosynthesis (DBT), which produces a three-dimensional (3D) image of the breast in the form of image slices. DBT allows the radiologist to "see through" the breast tissue for better detection and localization of breast cancer. By looking at both the CEDM images and the CEDBT images, a radiologist may be able to better detect residual breast cancer in a more cost-effective manner. Participation may last up to 18 weeks. Study procedures for this research are: * Undergoing 1-2 mammograms during and/or after your chemotherapy, but before primary breast surgery. * Before each mammogram, have a radiology technician inject a liquid contrast agent by inserting a needle into a vein. The chemotherapy port cannot be used to receive the contrast agent * Let the research team record information from your medical record related to your condition and the treatment you receive. * Give permission to collect leftover tissue from your diagnostic biopsy and breast surgery.

Conditions

  • Breast Cancer
  • Locally Advanced Breast Cancer
  • Neoadjuvant Chemotherapy
  • HER2-positive Breast Cancer
  • Triple Negative Breast Cancer
  • TNBC, Triple Negative Breast Cancer

Interventions

  • CEDMDiagnostic test

    Contrast Enhanced Digital Mammography

  • CEDBTDiagnostic test

    Contrast-Enhanced Digital Breast Tomosynthesis

  • Omnipaque 350mgI/mL Solution for InjectionDrug

    Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accuracy of (CEDM+CEDBT) to predict NAC treatment effectsTime frame: Immediately after definitive breast surgery, up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stony Brook Breast Center

    Stony Brook, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.